Railroad Operator CSX Keeps Chugging Along
After a tough 18 months, CSX looks poised for clearer track ahead, beginning with Tuesdays’ earnings report.
Yahoo: Verizon Is Still the Bidder to Beat
Yahoo may be attracting attention from a number of potential buyers, but Verizon has the heft to guarantee itself a win.
Why Germany’s Griping on ECB Policy Misses the Mark
Germany has stepped up criticism of the ECB. It would do better to lead political efforts in Europe to boost growth.
Putting M&A Hopes on Hold in Europe
The U.K. antitrust watchdog has come out publicly against the merger of CK Hutchison’s Three network and Telefónica’s O2. Deal makers will need new approaches.
Nvidia Won’t Run Out of Road
Shares of chip maker Nvidia have gotten expensive, but a focus on games, cars and the cloud can still pay off.
China’s Missed Opportunities to Kill Zombie Companies
A recent flurry of Chinese defaults may just be a list of companies Beijing decided aren’t important enough.
Fresh Chinese Bank IPO Turns Sour in a Hurry
Bank of Tianjin, which counts ANZ as a major shareholder, disclosed a disconcerting “risk incident” just days after its IPO.
Why Alcoa Shares Can Shine Brighter
As Alcoa kicks off earnings season on Monday, there are reasons to believe its stock is still underappreciated.
Iran and Oil: You Ain’t Seen Nothing Yet
Iran’s feared return to the oil market has been underwhelming, but just wait.
The Market Might Lose This Fight With the Fed
The Federal Reserve is dovish on rates, but maybe not quite as dovish as investors think.
Media Stocks: Digital Disruption Isn’t a Death Knell
How bad things look for TV advertising depends in part on how investors define TV.
Valeant’s Debt-Deal Wrinkle: What It Says About Profits
A part of Valeant’s agreement with lenders suggests its own doubt about near-term earnings.
Wall Street’s First Quarter Looks More Like a Dime
Trading activity stayed weak in March, but shares of big banks still look cheap.
Pfizer: Slim Down to Bulk Up the Stock
With Allergan in the rearview mirror, Pfizer should move to break itself up.
Sumitomo Corp.: Where Commodity Pain Has Yet to Be Acknowledged
Despite some write-downs, major Japanese trading house Sumitomo sounds too hopeful about its exposure to commodities.
How Fickle Markets Are Challenging ECB’s Mario Draghi
A central bank’s work is never done, it seems. The ECB faces challenges from market moves.
Why Not to Rush Into Pharma’s Bargains
The pharmaceuticals sector is trading at its lowest valuation in over two years. Investors eyeing Europe’s big pharma companies should tread carefully.
Be the first to comment on "Markets: Latest Financial Topics from The Wall Street Journal"